Epitomics

Aushon Biosystems has launched Cira, its new multiplex immunoassay platform.

Bio-Rad this week introduced its V3 Western Workflow, a portfolio of products for Western blotting that include its TGX Stain-Free gels, ChemiDox MP imaging system, and TransBlot Turbo transfer system.

Epitomics has released new rabbit monoclonal antibodies for a variety of proteins including phospho LRRK2, TTF1, CHx10, and LSD1.

NanoInk this week released its new NanoArray Assay System for the automated analysis of its protein NanoArray assays.

The company, called SISCAPA Assay Technologies, will offer assay development to pharmas and CROs and has tapped antibody firm Epitomics to produce reagents for the system and sell SISCAPA kits. So far, the company has licensed the technology to Pfizer for internal use.

The work will focus on developing antibodies to tryptic peptides derived from protein biomarkers in human plasma for mass spec workflows like SISCAPA and immuno-MALDI.

Under its contract with SAIC-Frederick, Epitomics will develop high affinity and renewable agents to capture tryptic peptides derived from human plasma protein biomarkers.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.